Analysis of Metabolic Activity in Respectable, Early-Stage, and Hormone Receptor Positive/Her2 Negative Breast Cancer

Inclusion Criteria

• Male or female patients >= 18 years of age
• Have HR+ (i.e. estrogen receptor positive (ER+)/progesterone receptor negative (PR-), ER-/PR+ or ER+/PR+)/Her2- breast cancer previously diagnosed by biopsy
• Have early stage, clinical or anatomic stage I, II or III breast cancer (cT2N0, cT2N1, cT3N0)
• Candidates for intended curative primary resection (mastectomy) who have not had neoadjuvant therapy (endocrine/hormonal therapy, chemotherapy with or without immunotherapy)
• Willing to undergo mandatory intraoperative small excisional and core biopsies (3-6 passes) of tumor and normal tissue for research purposes at the time of proposed surgical resection
• All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry

Exclusion Criteria

• Is currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study
• Has triple negative (ER-/PR-/Her2-) or HER2+ breast cancer
• Concomitant active malignancy
• Is of child-bearing potential who has not had a recent negative pregnancy test done outside of this clinical trial (i.e., as part of standard preparation for diagnosis and treatment for her cancer)